Limits...
Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics.

Calza L - Drug Healthc Patient Saf (2009)

Bottom Line: Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia.Its chemical and pharmacokinetic properties (with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike metabolically mediated drug-drug interactions.This article reviews the most recent data on the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of this statin for the treatment of hypercholesterolemia.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

ABSTRACT
Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) cholesterol and total cholesterol significantly more than atorvastatin, simvastatin, and pravastatin, and triglycerides significantly more than simvastatin and pravastatin. In healthy subjects with normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly decreased the incidence of cardiovascular events. Its chemical and pharmacokinetic properties (with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike metabolically mediated drug-drug interactions. This article reviews the most recent data on the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of this statin for the treatment of hypercholesterolemia.

No MeSH data available.


Related in: MedlinePlus

Algorithm for drug-therapy of hypercholesterolemia.Abbreviation: LDL, low-density lipoprotein.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108688&req=5

f2-dhps-1-025: Algorithm for drug-therapy of hypercholesterolemia.Abbreviation: LDL, low-density lipoprotein.

Mentions: The most appropriate algorithm for pharmacologic therapy in patients with hypocholesterolemia is summarized in Figure 2.


Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics.

Calza L - Drug Healthc Patient Saf (2009)

Algorithm for drug-therapy of hypercholesterolemia.Abbreviation: LDL, low-density lipoprotein.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108688&req=5

f2-dhps-1-025: Algorithm for drug-therapy of hypercholesterolemia.Abbreviation: LDL, low-density lipoprotein.
Mentions: The most appropriate algorithm for pharmacologic therapy in patients with hypocholesterolemia is summarized in Figure 2.

Bottom Line: Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia.Its chemical and pharmacokinetic properties (with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike metabolically mediated drug-drug interactions.This article reviews the most recent data on the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of this statin for the treatment of hypercholesterolemia.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

ABSTRACT
Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) cholesterol and total cholesterol significantly more than atorvastatin, simvastatin, and pravastatin, and triglycerides significantly more than simvastatin and pravastatin. In healthy subjects with normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly decreased the incidence of cardiovascular events. Its chemical and pharmacokinetic properties (with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike metabolically mediated drug-drug interactions. This article reviews the most recent data on the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of this statin for the treatment of hypercholesterolemia.

No MeSH data available.


Related in: MedlinePlus